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ABSTRACT 
 
Background: Early neurological deterioration (END) following acute stroke is associated with poorer 
long-term outcomes. Identification of patients at risk could assist early monitoring and treatment 
decisions. This review summarised the evidence describing non-radiological biomarkers for END. 
Summary: Electronic searches from January 1990-March 2017 identified studies reporting a 
blood/cerebrospinal fluid (CSF)/urine biomarker measurement within 24 hours of acute stroke and at 
least two serial assessments of clinical neurological status (<24 hours and <7 days). 
Out of 12,895 citations, 82 studies were included, mostly focusing on ischaemic stroke. Using higher 
neurological thresholds, the n-weighted END incidence for ischaemic stroke was 11.9% (95% 
confidence interval CI 11.4-12.4%) and 18.6% (17.9-19.2%) for lower thresholds. Incidence decreased 
with advancing study publication year (Pearson r-squared 0.23 and 0.15 for higher and lower threshold 
studies). After classification into 3 broad categories, meta-analysis showed that biomarkers associated 
with increased END risk (n; fixed-effects mean difference; 95% CI) were: “metabolic” [glucose 
(n=9781; 0.90mmol/l; 0.74-1.06), glycosylated haemoglobin (n=3146; 0.33%; 0.19-0.46), low-density 
lipoprotein (n=5476; 0.13mmol/l; 0.05-0.20), total cholesterol (n=4822; 0.19mmol/l; 0.10-0.29), 
triglycerides n=4880; 0.10mmol/l; 0.04-0.15), urea (n=1351; 0.55mmol/l; 0.14-0.96), decreasing 
albumin (n=513; 0.33g/dl; 0.05-0.61)]; “inflammatory & excitotoxic” [plasma glutamate (n=688 
60.13umol/l; 50.04-70.22), CSF glutamate (n=369; 7.50umol/l; 6.76-8.23), homocysteine (n=824; 
2.15umol/l; 0.68-3.61), interleukin-6 (n=231; 24.80pg/ml; 21.72-27.88), leucocytes (n=3388; 
0.41x109/L; 0.21-0.62), high-sensitivity c-reactive protein (n=1707; 3.79mg/l; 1.23-6.35)]; and 
“coagulation / haematological” [fibrinogen (n=3132; 0.32g/l; 0.25-0.40); decreasing haemoglobin 
(n=3586; 2.38g/l; 0.15-4.60)]. 
Key messages: Declining incidence of END may represent improving care standards but it remains a 
frequent occurrence. Although statistical associations exist between biomarkers and an increased risk 
of END, the most promising still need prospective evaluation to determine their additional value relative 
to baseline radiological and clinical characteristics.  
Introduction 
Early neurological deterioration (END) describes the worsening of symptoms in the hours and days 
following acute stroke and is associated with worse outcomes [1]. Although it may reflect natural 
progression of the underlying pathophysiological process, END is not inevitable and occurs less often 
when care is provided within a formal stroke unit setting [2]. Associations include age, diabetes, 
cerebral oedema, haematoma expansion (particularly in the context of hypertension), haemorrhagic 
conversion of infarction with or without reperfusion treatment and systemic physiological disturbances 
such as blood pressure variability and pyrexia [1-5]. 
Variations in case-mix and END definitions have produced wide estimates of incidence, with a previous 
review reporting frequencies of 2.2% to 37.5% at 24 hours since onset [1]. Fewer patients will be 
labelled with END at a higher clinical threshold than a lower threshold. It may be also expected that the 
probability of END will increase with longer time windows between first and second measurements of 
clinical status. By any definition, prediction of END risk at the point of admission may identify patients 
in need of additional monitoring, investigations and a lower threshold for clinical intervention.  
Clinical and radiological associations with END have already been described in detail [1]. A molecular 
biomarker is particularly attractive for predicting END as it could be developed into a point-of-care test 
applied at the beginning of the patient care pathway to provide additional subclinical information about 
prognosis. A recent horizon scanning review of stroke biomarkers identified associations between END 
and markers of excitotoxicity (glutamate and glycine), pro-inflammatory cytokine interleukin-6 and 
fluorescent molecular peroxidation products [3]. However, it did not consider information about 
possible biomarkers contained within reports from large clinical studies or perform meta-analysis.  In 
view of the increasing focus upon stratification of stroke patients for different emergency treatments 
and levels of monitoring intensity, we undertook an in-depth review across a broad range of clinical 
studies to describe END frequency, categorize  molecular biomarkers into a simple taxonomy and 
consider their potential as predictors for END risk, with meta-analysis when possible. 
 
Methods 
Medline and Embase were searched from January 1990-March 2017 for interventional or observational 
studies reporting a blood, CSF or urine biomarker measurement early after acute ischaemic and/or 
haemorrhagic stroke, including at least two serial assessments of clinical neurological status (baseline 
<24hrs and repeated within 7 days). The protocol was registered with the PROSPERO review database: 
ID CRD42017060167. 
The search strategy is described in Error! Reference source not found.. Only studies written in 
English were included. Studies were initially screened by title and abstract. Full text versions were then 
sought but authors were not contacted. Data items (Appendix 2) were extracted using a pre-defined 
proforma including setting, population, participant demographics and baseline characteristics, 
biomarkers, time of biomarker measurement and author definitions for END, ischaemic END (IS-END) 
and END following haemorrhagic stroke (ICH-END). Unclear study descriptions were reviewed by 
both authors. Studies were excluded which specifically included sub-arachnoid haemorrhage or other 
vascular malformations, and from settings which report highly unusual clinical stroke care practices 
(e.g. brain imaging was not routinely performed). Due to the heterogeneity of studies and information 
available, no formal assessment of risk of bias was possible. 
Review Manager (Revman) Version 5.3 [4] was used for meta-analysis of individual biomarkers where 
a mean and standard deviation (SD) were reported for each group. Standard conversions were made to 
common units. A fixed effects model was used and mean difference (95% CI) is reported. No additional 
analyses were performed. If a biomarker was described by only one study, the results are presented 
within the meta-analysis results if the data were normally distributed. All studies reporting data which 
were not normally distributed, and those which could not be combined because of lack of information 
about the END definition, are described but are not included in the meta-analysis.     
Results  
Appendix 3 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) [5] flowchart of studies; 86 were included from 12,895 initial citations. Table 1 summarises 
studies grouped by author-defined neurological thresholds for END. 
[TABLE 1] 
Using a higher neurological threshold, 35 IS/mixed studies had n-weighted END incidence of 11.9% 
(95% CI 11.3-12.4%), whereas 43 lower-threshold studies had incidence of 18.0% (95% CI 17.4-
18.7%) (Appendix 4). Three higher-threshold ICH studies had an incidence of 12.3% (95% CI 9.2-
15.4%), and a single lower threshold ICH study [6] had an incidence of 23.0% (95% CI 17.9-28.1%) 
(Appendix 4). 
There was a trend of declining END incidence with advancing study publication year which persisted 
when stratified by time window and definition (Error! Reference source not found., Error! 
Reference source not found.).  
[FIGURE 1] 
[FIGURE 2] 
Biomarker data are summarised in three categories: a) metabolic (Table 2); b) inflammatory and 
excitotoxic (Table 3); c) coagulation and haematological (Table 4).  Studies reporting non-parametric 
biomarker data, results based on a threshold and biomarkers described in single studies only were 
unsuitable for meta-analysis and are tabulated separately in Appendix 5, 6 and 7 and are referenced by 
their entry in each Appendix. Citations in bold font concur with the output from the relevant biomarker 
meta-analysis. 
Metabolic biomarkers 
[TABLE 2] 
Glucose was significantly higher with IS-END [2, 7-36] and ICH-END [37], which may have numerous 
explanations including poorer collateral flow, endothelial damage, increased oxidative stress and 
lactate, haemorrhagic transformation and dysregulation of glucose energy metabolism [38]. This was 
mirrored in glycosylated haemoglobin (HbA1c), a marker of chronic raised glucose, also predicting 
END [9, 23, 25, 26, 29, 30, 35, 39] [5K]. One study stratified the effect of glucose by the presence of 
diabetes mellitus, finding elevated glucose level was associated with END in non-diabetics [38].  
Raised total cholesterol, low-density lipoprotein (LDL), triglycerides and triglyceride/HDL ratio were 
predictive of IS-END, however lower levels of these predicted ICH-END [9, 23, 25, 26, 35, 39-45] 
[5M, 5S-U]. This concurs with current understanding about cholesterol and the risk of IS/ICH. 
Hypercholesterolaemia is well described as a modifiable risk factor for IS and lipid-lowering agents are 
used in stroke prevention. Conversely, possibly because a degree of cholesterol deposition plays a role 
in maintaining the arterial wall, risk of rupture and haemorrhage is lower in patients with higher total 
cholesterol [46]. Furthermore, post-hoc analysis of the Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial showed early treatment post-IS with high-dose lipid-lowering 
agents increased ICH risk [47]. There was no association between high-density lipoprotein and END 
[9, 23, 29, 35, 40-44] [5L]. 
Increased serum albumin appeared to reduce the risk of END. The included studies did not suggest why 
[25, 26], however a 2004 study found higher albumin decreased the risk of poor outcome at 3 months 
indicating a possible link between pre-stroke health and END [48]. A higher ratio of CSF: serum 
albumin predicted END as a marker of albumin influx into the CSF following blood-brain barrier 
dysfunction in stroke [49]. 
The liver enzyme AST metabolises glutamate. Higher levels of liver enzyme AST (aspartate 
transaminase/glutamate-oxaloacetate transaminase), which metabolises glutamate, were associated 
with lower incidence of END [9, 11, 25, 26]. Glutamate may be excitotoxic in stroke [50], therefore 
AST may be neuroprotective by reducing metabolic activity [11]. However, ALT (alanine 
transaminase/glutamate pyruvate transaminase) was not significantly different in END. Increased 
bilirubin was associated with END in one study [5F]. 
Further results from studies which could not be combined into meta-analysis are shown in Appendix 5. 
END was associated with higher blood urea nitrogen: creatinine ratio [5H-I], urine specific gravity [5Z], 
urea [9, 22, 25, 26, 29]  and urinary albumin: creatinine ratio (UACR) [5V-X], markers of 
dehydration/impaired renal function. Of two studies of plasma osmolality/osmolality [5Q-R], one found 
an association with END, although the one direct study of plasma viscosity did not reach significance 
[7Q]. Patients with dehydration may suffer END due to increased plasma viscosity and/or lower 
cerebral perfusion, but these biomarkers for renal function and fluid status may also indicate co-
morbidities and limited physiological reserve. 
Uric acid (UA), an antioxidant, was found in one study to decrease with time following stroke and a 
greater decrease by day 7 was associated with END [5Y], possibly because higher baseline UA is 
associated with a greater vascular risk. 
Plasma adrenomedullin was higher in ICH-END but in a single study did not improve the predictive 
value of the NIHSS score [5B]. 
Creatinine phosphokinase was associated with ICH-END in one study, however this was only narrowly 
significant (p=0.043) in a study where ~60 variables were analysed and no adjustment for multiple 
comparisons was made [5I]. 
Adiponectin [5A], alkaline phosphatase [5D], alanine aminotransferase [9, 11, 25, 26], aspartate [5E],  
acute decrease in magnesium [5N], methionine [5O], sodium [9, 22, 29], potassium [9, 22, 29], 
creatinine [9, 22, 26, 29], estimated glomerular filtration rate [10, 18, 29] [5J] and uric acid [12, 25, 26] 
showed no association with END. 
Inflammatory & excitotoxic biomarkers  
[TABLE 3] 
Excitotoxic amino acids are associated with damage in stroke, particularly glutamate [50], which 
induces depolarisations around the infarct that disrupt ionic homeostasis, increasing infarct volumes 
[51]. In meta-analysis, glutamate was associated with END in CSF [24, 52], although this was not 
corroborated by a further small study [6O]. Plasma glutamate was also associated with IS-END [8, 11, 
52, 53] [6N]. Cysteine [6H], homocysteine [23, 35] [6S] and CSF glycine [6Q, 6R] were also associated 
with END in at least one study.  Phosphorylated axonal subunit-H, a marker of axonal injury, was raised 
in ICH however it did not improve on the PPV of NIHSS alone [6AI]. Glutamine [6P], proline [6AJ] 
and taurine [6AS] were not associated with END. 
Markers of inflammatory immune response were also raised in END, which may suggest ongoing 
inflammation or an increased risk associated with underlying infection. Standard c-reactive protein 
(CRP) was significantly different in ICH [37] and in some studies of IS [6G]. However, high-sensitivity 
CRP (hsCRP) predicted END in IS [12, 23, 41, 43, 54], which is supported by studies showing that 
raised hsCRP is also associated with IS risk [55]. Leucocyte count was elevated in END in IS [7-9, 11, 
16, 17, 22, 25, 26, 29, 35, 36, 39, 45, 53, 56, 57] [AD] and ICH [6, 37]. Neutrophil count was raised in 
END in one ICH study [6AF], as were segmented neutrophils in IS [6AM]. (s)ICAM-1, which is 
responsible for neutrophil adhesion [36], was associated with END in two studies [6U, 6AO]. Pro-
inflammatory cytokines interleukin-6 [6Z] and TNFa (in plasma and CSF) [6AT-U] were raised in 
END. TNFa receptors sTNF-R1/R2 were not associated with END [6AP-AQ]. 
There were several notable findings amongst studies which could not be combined in the meta-analysis 
(Appendix 6). 
Molecules with a role in the inflammatory response included 15-deoxy prostaglandin J2 (15-dPGJ2), 
which appeared to be neuroprotective against END in atherothrombotic infarcts, but not in other infarct 
types [6A-B], whereas elevated beta-defensin 2 [6D] and soluble IL-4 receptor [6Y] improved 
prediction of END over clinical models. 
Nitric oxide (NO) has both neuroprotective and neurotoxic roles in brain injury. NO-metabolite 
predicted END independent of CSF glutamate levels [6AG], whereas L-arginine, a substrate for nitric 
oxide generation and potential marker of NO-mediated brain damage, was lower in patients with END 
[6AA-AB].  
In a study of monocyte subsets, an increased proportion of CD14highCD16- monocytes, was associated 
with END by 7 days, potentially because this meant fewer CD14highCD16+ monocytes were present 
[6E]. The latter produce IL-10, which has been suggested to have a beneficial anti-inflammatory effect 
in stroke [57]. However, while a study of numerous cytokines and receptors found a significant 
association between IL-10 and END it was concluded that it did not predict END better than clinical 
assessment alone [6V]. The study found no association with IL-1B or IL-1RA [6W-X] and END. In a 
study focussing upon acute penetrating artery stroke, low baseline CD34+ cells, markers of endothelial 
function, were associated with END [6F].  
In a CSF study of monoaminergic neurotransmitters, only elevated 5-hydroxyindoleacetic acid (5-
HIAA) was associated with END [6C]. Norepinephrine [6AH], 5-hydroxyindoleacetic acid (5-HIAA) 
[6C], homovanillic acid (HVA) [6T] and 3,4-dihydroxyphenylacetic acid (DOPAC) [6I] were not. 
 Two indicators of blood-brain-barrier compromise were associated with END: CSF:serum albumin 
ratio [5C] and change in matrix metalloproteinase-9 (MMP-9) [6AE]. Fluorescent molecular 
peroxidation products (FMPPs), markers of oxidative damage hypothesised to promote blood-brain 
barrier degradation, were significantly associated with END following thrombolysis [6L]. 
Cysteine [6H], gamma-aminobutyric acid [6M], plasma glycine [6R], p-selectin [6AK], SE-selectin 
[6AN], segmented & band leucocytes [6AL] and sVCAM-1 [6AR] were not significantly different in 
END. 
A single study showed a non-significant trend towards elevated CSF lactate indicating a higher risk of 
END [6AC]. Although lactate is generally a useful marker of ischaemia, the low capacity for anaerobic 
metabolism within neurones may result in the ability to detect only large volumes of vulnerable tissue. 
Coagulation and haematological biomarkers 
[TABLE 4] 
Pro-coagulation factors fibrinogen (In IS [7, 8, 11, 15-17, 28, 31, 35, 36, 45, 53, 56] [7M]; in ICH [6, 
37]) and factor VIII [7I] were associated with END, as was INR, a measure of the intrinsic coagulation 
pathway [29, 36, 42]. A greater 72hr decrease in procarboxypeptidase U, which inhibits fibrinolysis, 
predicted END, which was hypothesised to be utilised by thrombus growth [7T]. Measures of 
endogenous anti-coagulants protein C [7B], antithrombin-III [7E] and thrombin-antithrombin III 
complex [7Y] did not predict END. 
Aspirin non-responsiveness may also play a role in END. Platelet reactivity to aspirin (ARU) at baseline 
was not associated with END, however a high degree of change in ARU was associated with END [7A]. 
Poor response to aspirin measured by PFA-100s, a platelet aggregation assay, was also associated with 
END [7D]. 
Lower haemoglobin was associated with END in IS [9, 22, 25, 29, 42], which may suggest patients with 
reduced oxygen-carrying capacity are at greater risk. 
Further studies found significant associations which could not be combined in meta-analysis [Appendix 
7]. Both CSF and plasma ferritin were associated with END independently of ultimate infarct volume 
and were hypothesised to be related to excitotoxic mechanisms in stroke, however only the CSF ferritin 
finding was replicated in a later study [7K-L]. Neither CSF nor plasma iron were associated with END 
[7O-P]. 
Higher von Willebrand factor was associated with END [7AA]. In the same study, three markers of 
thrombin generation (prothrombin F1+2 [7V], fibrin d-dimer [7F] and thrombin-antithrombin 
complexes [7Y]) were associated with END on univariate analysis. Six studies showed increased D-
dimer associated with END, three of which reported the associated as significant. 
Activated partial thromboplastin time [7C], factors VIIc and VIII(c) [7H-J] haematocrit [7N], platelets 
[7R], prolyl carboxypeptidase [7S], prothrombin fragment 1+2 [7U], prothrombin time [7V], soluble 
fibrin monomer [7W] and thrombin time [7X] were no different with END. 
Discussion 
Depending upon the threshold used, IS-END incidence ranged from 11.9% (higher threshold definition) 
to 18.6% (lower threshold definition), indicating that it remains a significant clinical challenge. As only 
four studies focussed upon ICH in isolation there is limited data about ICH-END incidence in relation 
to biomarkers, but amongst the three using a higher threshold, 12.2% deteriorated, comparable to 
ischaemic stroke. In cohort studies, END rates up to 30% have been reported following ICH [58], but 
differences are likely to reflect whether the clinical setting is a stroke unit without pre-selection or a 
specialist neurosurgical unit. Overall, incidence of END fell with advancing study publication year, 
independently of neurological threshold and time window. This may reflect improvements in stroke 
care including reperfusion treatments and/or changes in case-mix. 
Meta-analysis identified a number of biomarkers, both routinely performed and novel, associated with 
END. The likely explanations for these associations are diverse and a direct link to mechanisms for 
END cannot be inferred. Some of the biomarkers described have been considered by trialists as 
contributors themselves towards the process of neuronal death, but intervention has not consistently 
shown improved outcomes e.g. insulin for blood glucose lowering [59]. However, there is consistent 
trial evidence that pro-active assessment for pyrexia, swallowing difficulties and dehydration can 
reduce dependency, possibly through avoidance of END for some patients. It is therefore not surprising 
that infection (e.g. leucocytes and high-sensitivity CRP) and fluid status/renal function biomarkers 
(urea, albumin) may identify patient groups particularly at risk. The link to END may be through the 
physiological consequences of infection and dehydration such as increased plasma viscosity and 
fluctuations in cerebral perfusion.    
Other biomarkers may reflect the volume of subclinical cerebral tissue injury during acute stroke and 
hence indicate a greater probability of further clinical progression, particularly those molecules which 
are specific to neuronal tissue or involved in neurotransmission. For example glutamate, which is also 
implicated in the progression of cellular death through excitotoxicity [51,53], was associated with END 
when measured in CSF and plasma. We did not identify any studies which related these biomarkers to 
advanced imaging techniques such as MRI or CT perfusion, which could provide mechanistic evidence 
and indicate their potential for further development as rapid near-patient tests. There is already good 
evidence that perfusion mismatch indicates patients at risk of deterioration [60], which can be averted 
by reperfusion therapy [61], but a point of care biomarker with sufficient accuracy to alter clinical care 
is likely to have wider applicability and availability for the global stroke population.     
In line with growing evidence that inflammation is key to the development of atherosclerosis and plaque 
rupture, associations have been shown between biomarkers implicated in inflammatory pathways and 
END. These may reflect the severity of pre-existing atheroma and so indicate poorer local perfusion 
and/or collateral supply [62]. Elevated HbA1c, increased LDL, total cholesterol and triglycerides may 
also indicate a greater burden of background atheroma and vulnerability to tissue ischaemia.  The 
relationship between haematological biomarkers and END is likely to be more direct and immediate. 
Fibrinogen, a pro-coagulant factor, may reflect the probability of large, thrombin-rich clot formation 
and progression, whereas impaired penumbral oxygen delivery may explain the association between 
END and reduced haemoglobin.  
A recent review identified numerous challenges when developing biomarkers for stroke diagnosis 
which are pertinent to predicting END [3]. These include the non-specificity of biomarkers to brain 
tissue and the inability of molecules to cross the blood-brain barrier. Simultaneous measurement of 
multiple biomarkers in a single panel has been proposed, combined with recent developments in 
genomics and proteomics, approaches which have not yet been taken in END. However, as reported by 
the Stroke-Chip study following evaluation of an assay panel for stroke diagnosis, many biomarkers are 
not independent of one another and may not be significantly better than clinical judgement and 
radiological data [63]. Amongst investigations which are already routinely available clinically, the 
results of the meta-analysis suggest that it would be reasonable to increase monitoring intensity for 
those acute stroke patients where venepuncture reveals a low haemoglobin or elevated glucose, 
glycosylated haemoglobin, urea, osmolality, CRP, ESR or leucocytes.     
Limitations 
This review included only summary results from English language studies indexed in Medline and 
Embase, and authors were not contacted for data. Most articles provided insufficient information to 
permit assessment of bias. For example, many studies reported that the biomarker results were 
concealed from the END assessor, but it was unclear whether they were aware of other results which 
could cause unblinding such as clinical brain imaging. Formal quality assessment of the included studies 
was not performed as interpretation would have been difficult due to their early stage, extreme 
methodological variability, and the lack of information presented. Sample size estimations were rarely 
reported. Despite proven associations with patient outcomes, studies did not report other clinical or 
radiological data which could assist with exploration of mechanisms for biomarker responses and their 
clinical utility. 
Recommendations 
The biomarkers identified by this review which have demonstrated strong associations with END in 
more than one cohort have the potential to be clinically useful, but further studies are required to prove 
diagnostic utility. These should include reports of standardised clinical and radiological data, such as 
the Alberta Stroke Program Early CT Score (ASPECTS) [64] score for ischaemic stroke, and 
haematoma volume for ICH [58]. Other novel biomarkers with a promising pathophysiological basis 
were considered by single studies, but have not been further developed. Significant investment is needed 
if affordable and practical tests are to become available for integration into effective clinical monitoring 
and response protocols.  
As END remains a clinical entity with various definitions, standardisation is necessary to allow 
meaningful comparison and combination of future studies. In the meantime, authors should determine 
a priori which definition is to be used. The timing of biomarker sampling and assessment of END 
should be at clinically important intervals, for example during thrombolysis/thrombectomy windows. 
Other factors which may influence END incidence (e.g. time from onset, and 
thrombolysis/thrombectomy treatment), should be collected within studies that are large enough to 
allow meaningful analysis of multiple variables.  
Conclusions 
Although the incidence of END following acute stroke may be decreasing, it remains a common 
occurrence. This systematic review has identified biomarkers associated with END in predominantly 
exploratory studies or from incidental observation during clinical trials. Their value in relation to key 
clinical and radiological characteristics is unclear, and none can yet be recommended for use. Further 
studies are required for validation and development of clinically useful tests which stratify patients into 
higher and lower risk groups, and ultimately improve clinical outcomes through END prediction. 
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